Rapid Detection of HLA Genes Expression in Peripheral Blood Mononuclear Cell of Gastric Cancer Patients by Reverse Transcriptase Polymerase Chain Reaction

Author(s):  
Yi Zhang ◽  
Yang Liu ◽  
Nan Lu ◽  
Sheng-Mei Zhao ◽  
Gui Xi Zheng ◽  
...  
2008 ◽  
Vol 11 (4) ◽  
pp. 206-213 ◽  
Author(s):  
Kimberly Moore Dalal ◽  
Yanghee Woo ◽  
Kaitlyn Kelly ◽  
Charles Galanis ◽  
Mithat Gonen ◽  
...  

Author(s):  
Gabriel Neto Oliveira ◽  
Olavo Magalhães Picanço Jr ◽  
Artemis Socorro do N. Rodrigues

The objective of this study was to examine the association between the XRCC1 A910G polymorphism in gastric cancer patients in the city of Macapá, State of Amapá, Amazonia, Brazil.  DNA samples were obtained from 102 individuals, of which 40 were cancer patients and 62 controls. Polymerase Chain Reaction (PCR) was carried out to detect polymorphism, followed by PCR-RFLP analysis with the restriction enzyme HhaI. Of the 40 patients analysed, 22.5% had the Thr910Thr (A/A) genotype, while Ala910Ala (G/G) and Thr910Ala (A/G) genotypes accounted for 25% and 52.5% of samples, respectively. In the control group, of the 62 samples analysed, 74.1% had the Thr910Thr (A/A) genotype, while Ala910Ala (G/G) and Thr910Ala (A/G) represented 9.6% and 16.1% of samples, respectively. Our findings demonstrate that A910G polymorphism was found in most of the patients with gastric cancer in the study population. The G allele was frequently found in the analysed samples, as also observed in the genotype frequency, where AG and GG genotypes were present in cancer patients. This is the first study in Brazil to report the association between A910G polymorphism and gastric cancer.


2005 ◽  
Vol 91 (3) ◽  
pp. 248-252 ◽  
Author(s):  
Marcos Tobias-Machado ◽  
Fernando Fonseca ◽  
Ana Paula Fantinato ◽  
Israel Bendit ◽  
Marcelo Langer Wroclawski ◽  
...  

Aims and background Sensitive reverse transcriptase-polymerase chain reaction-based techniques for detection of epithelial antigen expression, such as cytokeratin 19, in the peripheral blood mononuclear fraction of prostate cancer patients may allow the detection of tumor progression at A molecular level. Methods We studied cytokeratin 19 expression by reverse transcriptase-polymerase chain reaction in peripheral blood mononuclear cell samples of 10 control men and serially in 44 patients with prostate cancer every three months for 18 months. Results None of the 10 normal control men expressed cytokeratin 19 in their peripheral blood mononuclear fraction. In the patients, cytokeratin 19 positivity at entry was not associated with age, Gleason score, clinical stage, prostate-specific antigen or alkaline phosphatase. Interestingly, having at least one positive cytokeratin 19 result during follow-up correlated significantly with time to prostate-specific antigen progression (P = 0.049), especially in the subgroup of metastatic patients (P = 0.032). Conclusions We conclude that cytokeratin 19 expression by reverse transcriptase-polymerase chain reaction in the peripheral blood mononuclear cell fraction of prostate cancer patients correlates with time to prostate-specific antigen progression. Further studies are needed to confirm these findings.


Sign in / Sign up

Export Citation Format

Share Document